These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11590255)

  • 1. The role of inflammation in the anaemia of end-stage renal disease.
    Stenvinkel P
    Nephrol Dial Transplant; 2001; 16 Suppl 7():36-40. PubMed ID: 11590255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress.
    Stenvinkel P; Bárány P
    Nephrol Dial Transplant; 2002; 17 Suppl 5():32-7. PubMed ID: 12091605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation.
    Icardi A; Paoletti E; De Nicola L; Mazzaferro S; Russo R; Cozzolino M
    Nephrol Dial Transplant; 2013 Jul; 28(7):1672-9. PubMed ID: 23468534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis?
    Orlic L; Mikolasevic I; Lukenda V; Racki S; Stimac D; Milic S
    Med Hypotheses; 2014 Dec; 83(6):798-801. PubMed ID: 25456789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients?
    Macdougall IC
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V73-78. PubMed ID: 15284364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines.
    Macdougall IC; Cooper AC
    Nephrol Dial Transplant; 2002; 17 Suppl 11():39-43. PubMed ID: 12386257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Malnutrition -- inflammation -- atherosclerosis (MIA syndrome) in patients with renal failure].
    Pawlaczyk K; Oko A; Lindholm B; Czekalski S
    Pol Merkur Lekarski; 2003 Oct; 15(88):334-41; discussion 341-3. PubMed ID: 14974361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyporesponsiveness to recombinant human erythropoietin.
    Drüeke T
    Nephrol Dial Transplant; 2001; 16 Suppl 7():25-8. PubMed ID: 11590253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter.
    Pecoits-Filho R; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2002; 17 Suppl 11():28-31. PubMed ID: 12386254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia in chronic renal disease: evaluation of inflammatory activity on erythropoiesis and iron metabolism in patients not submitted to dialysis treatment.
    De Lima GA; Mazzali M; Gentil AF; Plotegher L; Grotto HZ
    Clin Lab; 2012; 58(7-8):695-704. PubMed ID: 22997970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines.
    Tarakçioğlu M; Erbağci AB; Usalan C; Deveci R; Kocabaş R
    Mediators Inflamm; 2003 Feb; 12(1):15-9. PubMed ID: 12745544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaemia and inflammation: what are the implications for the nephrologist?
    Stenvinkel P
    Nephrol Dial Transplant; 2003 Nov; 18 Suppl 8():viii17-22. PubMed ID: 14607995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of inflammation on renal anaemia].
    Icardi A; Sacco P; Tarroni A; Cappelletti L; Cozzolino M
    G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease.
    Zyga S; Christopoulou G; Malliarou M
    J Ren Care; 2011 Mar; 37(1):12-5. PubMed ID: 21288312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia and chronic heart failure implications and treatment options.
    Anand IS
    J Am Coll Cardiol; 2008 Aug; 52(7):501-11. PubMed ID: 18687241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dialysis adequacy and response to erythropoietic agents: what is the evidence base?
    Locatelli F; Del Vecchio L
    Nephrol Dial Transplant; 2003 Nov; 18 Suppl 8():viii29-35. PubMed ID: 14607998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation.
    Macdougall IC; Cooper AC
    Eur J Clin Invest; 2005 Dec; 35 Suppl 3():32-5. PubMed ID: 16281956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors affecting the response to erythropoiesis-stimulating agents].
    Jauréguy M; Choukroun G
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S274-82. PubMed ID: 17373270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation in end-stage renal failure: could it be treated?
    Stenvinkel P
    Nephrol Dial Transplant; 2002; 17 Suppl 8():33-8; discussion 40. PubMed ID: 12147775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.